Aysche Landmann

ORCID: 0000-0003-3479-7612
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Systemic Lupus Erythematosus Research
  • Monoclonal and Polyclonal Antibodies Research
  • T-cell and B-cell Immunology
  • Autoimmune Bullous Skin Diseases
  • Urticaria and Related Conditions
  • Systemic Sclerosis and Related Diseases
  • Eosinophilic Disorders and Syndromes
  • Skin Protection and Aging
  • Atherosclerosis and Cardiovascular Diseases
  • Bioactive Natural Diterpenoids Research
  • Dermatology and Skin Diseases
  • Cutaneous lymphoproliferative disorders research
  • Reproductive System and Pregnancy
  • Inflammatory Myopathies and Dermatomyositis
  • Immune Cell Function and Interaction
  • melanin and skin pigmentation
  • Chronic Lymphocytic Leukemia Research
  • Plant-based Medicinal Research
  • Contact Dermatitis and Allergies
  • Multiple Sclerosis Research Studies
  • Psychedelics and Drug Studies
  • Bee Products Chemical Analysis
  • Cytokine Signaling Pathways and Interactions
  • Toxin Mechanisms and Immunotoxins
  • Forensic Toxicology and Drug Analysis

Heidelberg University
2012-2023

German Cancer Research Center
2012-2023

University Hospital Heidelberg
2020-2021

DKFZ-ZMBH Alliance
2013-2017

University of Münster
2012

Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed specifically for patients this entity, and topical systemic drugs are mostly used 'off-label'. The aim of the present guideline was to achieve broad consensus on treatment strategies CLE by European subcommittee, guided Dermatology Forum (EDF) supported Academy Venereology (EADV). In total, 16 participants were included in...

10.1111/jdv.14053 article EN Journal of the European Academy of Dermatology and Venereology 2016-11-16

In recent years it has been controversially discussed in the literature if smoking is associated with activity of cutaneous lupus erythematosus (CLE) and efficacy antimalarial agents.To investigate influence on disease severity treatment patients CLE using Core Set Questionnaire European Society Cutaneous Lupus Erythematosus (EUSCLE).A total 1002 (768 female, 234 male) different subtypes were included this cross-sectional study, which was performed 14 countries. Smoking behaviour assessed by...

10.1111/bjd.13006 article EN British Journal of Dermatology 2014-03-26

Objective The aim of the study was to assess efficacy and safety fumaric acid esters (FAEs) in patients with cutaneous lupus erythematosus (CLE). Methods In this 24-week, prospective, open-label, phase II pilot study, 11 CLE, refractory topical corticosteroids, were included. primary endpoint evaluation FAEs after 24 weeks treatment as assessed by Revised Cutaneous Lupus Disease Area Severity Index (RCLASI). Results Compared baseline, significant improvement mean total RCLASI activity score...

10.1177/0961203316644335 article EN Lupus 2016-05-05

5-(2-Aminopropyl)benzofuran (5-APB) and 6-(2-aminopropyl)benzofuran (6-APB) are benzofuran analogues of amphetamine belong to the category new psychoactive substances. Despite already published fatal 5- 6-APB intoxication after consumption both substances in most cases, no sensitive method for simultaneous detection quantification these compounds human blood samples has yet been developed. Therefore, an easy fast sample preparation specific high-performance liquid chromatography tandem mass...

10.1093/jat/bkab018 article EN Journal of Analytical Toxicology 2021-02-11

10.1055/s-0032-1326097 article DE Aktuelle Dermatologie 2013-02-25
Coming Soon ...